Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05890118 | Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule | PHASE1 | COMPLETED | 55 | — | — | Aug 1, 2023 | Nov 1, 2023 | Jan 10, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| Stelara | DRUG | A commercial formulation of ustekinumab for SC control (0.5mg) |
| RT-111 (0.5mg) | COMBINATION_PRODUCT | RaniPill capsule containing ustekinumab with a dose of 0.5mg |
| RT-111 (0.75mg) | COMBINATION_PRODUCT | RaniPill capsule containing ustekinumab with a dose of 0.75mg |